Company intelligence / Profile preview

Fletcher

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Fletcher Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of advanced cancers. The company's lead research centers on targeting the Prolyl endopeptidase-like (PREPL) protein, which plays a significant role in the metabolic and structural integrity of certain tumor types. By leveraging insights into protein degradation and metabolic vulnerabilities, Fletcher aims to create precision medicines for patients with limited treatment options. The company is currently in the pre-clinical stage, advancing its discovery programs toward candidate selection.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Fletcher.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fletcher.

Explore the full profile